Press releases

Boston Scientific (NYSE: BSX) today announced the close of its acquisition of the global surgical business of Lumenis LTD., a privately-held company that develops and commercializes energy-based...

Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the EXALT™ Model B Single-Use Bronchoscope, designed for use in bedside...

Boston Scientific Corporation (NYSE: BSX) has commenced enrollment in the HI-PEITHO clinical trial, a collaborative research study with the Pulmonary Embolism Response Team (PERT) Consortium and...

Boston Scientific (NYSE: BSX) announced that the U.S. Centers for Medicare & Medicaid Services (CMS) granted a New Technology Add-on Payment (NTAP) for single-use duodenoscopes, applicable to the...

Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.077 billion during the second quarter of 2021, growing 53.6 percent on a reported basis, 49.6 percent on an operational1 basis...

Today, Boston Scientific (NYSE: BSX) announced positive 24-month results from the PINNACLE FLX clinical trial assessing the safety and efficacy of the next-generation WATCHMAN FLX™ Left Atrial...

Boston Scientific Corporation (NYSE: BSX) today announced it exercised its option to acquire the remaining shares of Farapulse, Inc. The acquisition will complement the existing Boston Scientific...

Boston Scientific Corporation (NYSE: BSX) today announced it has completed CE Mark for the EXALT™ Model B Single-Use Bronchoscope, a single-use device designed for bedside procedures in the...

Data presented at hotline and late-breaking trial sessions today at the EuroPCR 2021 congress demonstrated positive procedural performance, including low rates of paravalvular leakage (PVL) and...

Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.752 billion during the first quarter of 2021. This represents growth of 8.2 percent on a reported basis, 5.6 percent on an...

Boston Scientific Corporation (NYSE: BSX) announced positive data from the TARGET study of the TheraSphere™ Y-90 Glass Microspheres (TheraSphere) – a type of radioembolization comprised of...

Boston Scientific Corporation (NYSE: BSX) announced it has received U.S. Food and Drug Administration (FDA) approval of the TheraSphere™ Y-90 Glass Microspheres, developed for the treatment of...

Boston Scientific (NYSE: BSX) today announced that it has entered into a definitive agreement with an affiliate of Baring Private Equity Asia (BPEA) to acquire the global surgical business of...

Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.708 billion during the fourth quarter of 2020. This represents a decline of (6.8) percent on a reported basis, (8.3) percent on...

Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval of its fourth-generation Vercise Genus™ Deep Brain Stimulation (DBS) System. The...

Boston Scientific (NYSE: BSX) today announced that it has entered into a definitive agreement to acquire Preventice Solutions, Inc., a privately-held company which offers a full portfolio of...

Boston Scientific (NYSE: BSX) has announced a limited market release of the WaveWriter Alpha™ portfolio of Spinal Cord Stimulator (SCS) systems. The unified portfolio of four MRI conditional,...

Boston Scientific Corporation (NYSE: BSX) generated net sales, based upon preliminary unaudited financial information, of approximately $2.71 billion during the fourth quarter of 2020. This...

Boston Scientific Corporation (NYSE: BSX) today announced that a stipulation of dismissal has been filed in the Nevro Corporation (NYSE: NVRO) patent infringement case against Boston Scientific in...

MARLBOROUGH, Mass., December 2, 2020 – Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the WaveWriter Alpha™ portfolio of Spinal Cord Stimulator...

Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a definitive agreement with Stark International Lux S.A.R.L., and SERB SAS, affiliates of SERB, a European...

Boston Scientific Corporation (NYSE: BSX) has announced it has initiated a global, voluntary recall of all unused inventory of the LOTUS Edge™ Aortic Valve System due to complexities associated...

Boston Scientific (NYSE: BSX) announced it has received U.S. Food and Drug Administration (FDA) approval of the Ranger™ Drug-Coated Balloon, developed for the treatment of patients with...

Boston Scientific Corporation (NYSE: BSX) has initiated the CHAMPION-AF clinical trial to evaluate the safety and efficacy of the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device within...

Boston Scientific Corporation (NYSE: BSX) generated sales of $2.659 billion during the third quarter of 2020. This represents a decline of (1.8) percent on a reported basis, (2.5) percent on an...

Boston Scientific (NYSE: BSX) today announced the European launch of the WaveWriter Alpha™ portfolio of Spinal Cord Stimulator (SCS) Systems. The portfolio, consisting of four MRI conditionali,...

Boston Scientific Corporation (NYSE: BSX) today announced it has initiated a controlled launch of the ACURATE neo2™ Aortic Valve System in Europe. This next-generation transcatheter aortic valve...

Boston Scientific Corporation (NYSE: BSX) today announced it has signed an investment agreement with an exclusive option to acquire Farapulse, Inc., a privately-held company developing a pulsed...

Boston Scientific Corporation (NYSE: BSX) announced it has received CE Mark and initiated a limited market release of the fourth generation Vercise Genus™ Deep Brain Stimulation (DBS) System in...

Boston Scientific (NYSE: BSX) announced that the U.S. Centers for Medicare and Medicaid Services (CMS) granted a New Technology Add-on Payment (NTAP) for the Eluvia™ Drug-Eluting Vascular Stent...

Boston Scientific Corporation (NYSE: BSX) generated sales of $2.003 billion during the second quarter of 2020. This represents a decline of (23.9) percent on a reported basis, (23.1) percent on an...

Boston Scientific Corporation (NYSE: BSX) announced it has received U.S. Food and Drug Administration (FDA) approval for the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device. Experience...

Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the LUX-Dx™ Insertable Cardiac Monitor (ICM) System, a new, long-term diagnostic device...

Boston Scientific (NYSE: BSX) today announced that the Centers for Medicare & Medicaid Services (CMS) has approved its application for a transitional pass-through (TPT) payment category to...

Boston Scientific (NYSE: BSX) announced the U.S. launch of the DIRECTSENSE™ Technology, a tool for monitoring the effect of radiofrequency (RF) energy delivery during cardiac ablation...

Boston Scientific Corporation (NYSE: BSX) completed the concurrent offerings of (i) 29,382,500 shares of its common stock, which includes the exercise in full by the underwriters of their option...

Boston Scientific Corporation (NYSE: BSX) announced the pricing of concurrent offerings of 25,550,000 shares of its common stock ("Common Stock") at a price to the public of $34.25 per share and...

Boston Scientific Corporation (NYSE: BSX) announced that it has commenced concurrent offerings of $750.0 million of shares of its common stock ("Common Stock") and $750.0 million of shares of its...

Boston Scientific Corporation (NYSE: BSX) completed a public offering of $1.7 billion aggregate principal amount of its senior notes. The public offering consists of $500.0 million of 1.900% notes...

Boston Scientific Corporation (NYSE: BSX) announced the pricing of a public offering of $1.7 billion aggregate principal amount of its senior notes under the company's shelf registration...

Boston Scientific (NYSE: BSX) today announced the final results from the UNTOUCHED study of the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) System presented at HRS 2020 SCIENCE, an...

Today, Boston Scientific (NYSE: BSX) announced positive 12-month results from the PINNACLE FLX clinical trial assessing the safety and efficacy of the next-generation WATCHMAN FLX™ Left Atrial...

Boston Scientific Corporation (NYSE: BSX) generated sales of $2.543 billion during the first quarter of 2020. This represents growth of 2.0 percent on a reported basis, 3.2 percent on an...

The COVID-19 pandemic has brought unprecedented challenges upon the global community and the many healthcare providers who are caring for patients. During this time of concern and disruption,...

Boston Scientific Corporation (NYSE: BSX) generated sales of $2.905 billion during the fourth quarter of 2019. This represents growth of 13.4 percent on a reported basis, 14.1 percent on an...

Boston Scientific Corporation (NYSE: BSX) generated sales, based upon preliminary unaudited financial information, of approximately $2.90 billion during the fourth quarter of 2019. This represents...

The EXALT Model D Duodenoscope is the first and only FDA cleared single-use duodenoscope on the market.

Boston Scientific completed a public offering of €900.0 million aggregate principal amount of 0.625% Senior Notes due 2027.

Boston Scientific announced a public offering of €900.0 million aggregate principal amount of 0.625% Senior Notes due 2027.

Boston Scientific announced the commencement of a cash tender offer for up to $1.0 billion of outstanding senior notes.

Today, Boston Scientific (NYSE: BSX) announced positive data for two devices within the peripheral drug-eluting product portfolio during separate late-breaking clinical trial presentations at...

Boston Scientific Corporation (the "Company") (NYSE:BSX) today announced that, pursuant to the previously announced cash tender offer (the "Tender Offer") for up to $1.0 billion aggregate...

"Our third quarter results reflect accelerated growth,” said Mike Mahoney, chairman and CEO, Boston Scientific. Read the October 23, 2019 announcement.

Boston Scientific announced the commencement of a cash tender offer for up to $1.0 billion of outstanding senior notes.

Study of abbreviated antiplatelet therapy for patients at high risk for bleeding after percutaneous coronary intervention.

Notably, key data from the EVOLVE Short DAPT study of the SYNERGY stent will be featured during a late-breaking science session.

System is designed to treat Parkinson's Disease symptoms by delivering precisely targeted electrical stimulation.

BTG acquisition brings best-in-class minimally-invasive technologies for procedures targeting cancer and vascular diseases to Boston Scientific.

"The consistent execution of our global teams continues to help us grow the majority of our businesses faster than the market,” said Mike Mahoney.

Momentum across business units and regions targeted to deliver top tier revenue growth and double-digit adjusted earnings per share growth with strong adjusted free cash flow.

Vertiflex acquisition adds the only FDA-approved, commercially available, minimally invasive interspinous spacer to Boston Scientific’s chronic pain portfolio.

WATCHMAN device findings could expand number of non-valvular atrial fibrillation (AFib) patients who can receive alternative treatment to lifelong use of blood thinners.

New clinical trial data further support use of Boston Scientific’s EMBLEM S-ICD System as first-line therapy for majority of ICD patients.

Acquisition of lumbar spinal stenosis treatment to expand portfolio of interventional pain therapies.

New stent system now available for treating patients with deep venous blockages.

"With our strong pipeline and category leadership strategy, we are confident in our top tier 2019 outlook,” said CEO Mike Mahoney. Read the April 2019 release.

Transcatheter aortic valve replacement technology for patients with severe aortic stenosis designed to minimize paravalvular leakage, offer controlled delivery and repositionability post deployment.

New data showcases safety & efficacy of recently acquired RF balloon-based, single-shot ablation technology when treating patients with AFib.

Company begins limited market release in Europe for next generation WATCHMAN device, intended to reduce the risk of stroke in people with non-valvular AFib.

Solutions for nutrition support and early detection of respiratory issues win and place at Connected Patient Challenge competition focused on chronic conditions.

Boston Scientific Corporation (NYSE: BSX) announced its completed public offering of senior notes.

Boston Scientific Corporation (NYSE: BSX) announced the pricing of a public offering of senior notes.

"Meaningful innovation and focused execution helped us deliver strong financial results in 2018," said CEO Mike Mahoney.

Rezūm patients experienced significant and sustained improvement in benign prostatic hyperplasia (BPH) symptoms and quality of life.

Advanced systems offer customizable therapy to treat Parkinson's symptoms.

Boston Scientific venous stent met VIRTUS trial primary effectiveness and safety endpoints in re-establishing blood flow.

Boston Scientific will webcast its conference call with financial results and business highlights for Q4 2018 and the full 2018 year.

Acquisition will expand structural heart portfolio to include transcatheter mitral annuloplasty repair system

Delaware court rules Edwards Lifesciences Infringes Boston Scientific patent

Transaction would expand Boston Scientific peripheral interventions portfolio with minimally invasive treatments for cancers and vascular conditions

"Through internal research and tuck-in acquisitions, we continue to bring meaningful innovations to market,” said CEO Mike Mahoney.

Court rules Edwards Lifesciences’ next-generation valve infringes Boston Scientific patent and grants right to enjoin sales in Germany.

The acquisition brings SpaceOAR, which decreases exposure to rectal radiation during prostate cancer radiotherapy, into the Boston Scientific portfolio.

Data support minimally invasive single-incision mesh procedure as a durable, safe and effective treatment for stress urinary incontinence.

Eluvia is the first peripheral vascular interventional technology approved in U.S. to offer a sustained release of a drug to treat peripheral artery disease.

First head-to-head trial assesses effectiveness of sustained drug release in interventional treatment for patients with blockages in femoropopliteal arteries.

New data at World Congress of Endourology demonstrate the Lithovue Empower device for kidney stone retrieval improves the OR experience.

Key data will include results from IMPERIAL trial evaluating ELUVIA drug-eluting stent and from REPRISE III study evaluating LOTUS Aortic Valve System.

Acquisition expands Boston Scientific portfolio of men's health in-office procedures with SpaceOAR, an adjunctive therapy for prostate cancer patients.

Acquisition will bolster Boston Scientific peripheral interventions portfolio with a treatment for venous obstructive disease

Boston Scientific acquisition adds the Sentinel® Cerebral Protection System, the only device cleared to protect patients against stroke risk in TAVR procedures.

"We're excited about the ways our differentiated pipeline will continue to drive our growth," said CEO Mike Mahoney.

Company does not endorse TRC's unsolicited mini-tender offer and recommends stockholders take no action.

Acquisition will add FDA-cleared Sentinel® Cerebral Embolic Protection System to expand Boston Scientific structural heart offerings.

Acquisition to expand Boston Scientific atrial fibrillation (Afib) ablation therapy offerings with innovative cryoballoon platform.

Data highlight the successful reduction of inappropriate shocks using the sensing filter in patients implanted with the EMBLEM™ S-ICD System.

Acquisition adds Rezūm®, a therapy for patients with symptomatic benign prostatic hyperplasia (BPH).

"Our consistently strong performance reflects our team's ongoing dedication,” said CEO Mike Mahoney.

Data demonstrated safety and effectiveness of VERCISE™ DBS System for controlling Parkinson’s symptoms.

European patent office revokes Edwards Lifesciences '550 patent.